29.9 C
New York
Saturday, June 13, 2026

Tag: patent

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading...

ALMORA BOTANICA GRANTED TWO GROUNDBREAKING PATENTS

A New Era of Ayurvedic Skincare Innovation LONDON, Aug. 7, 2025 /PRNewswire/ -- Almora Botanica, the pioneering science-first Ayurvedic skincare brand, has secured two groundbreaking...

Ascent Solar Technologies Establishes Rapid Thin-Film PV Delivery Process to Provide Customized Space Solar Products Ahead of Schedule on Mission Enabling Timelines

THORNTON, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascent Solar Technologies (“Ascent” or the “Company”) (Nasdaq: ASTI), the leading U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, continues to set precedence via its new standard for rapid delivery of space-mission enabling PV products. The Company has now delivered mission-optimized solar array blanket spaceflight hardware assemblies to multiple customers, each in under three weeks from order.

Lilly reports second-quarter 2025 financial results and raises guidance

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year...

Defiance Launches QPUX: 2X Leveraged ETF on Pure Quantum Companies

Defiance Launches QPUX: 2X Leveraged ETF on Pure Quantum Companies

Trend Micro Reports Earnings Results for Q2 2025

Increase of 9% in operating income to drive 20% operating margin*Increase of 43% in cash flow from operationsIncrease of 94% in Trend Vision One™...

Implantica announces second publication of groundbreaking 5-year results from the landmark RefluxStop® clinical study

VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed...

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Saint Herblain (France), August 7, 2025Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ®. IXCHIQ® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV.

123Invent Inventor Develops Security Device for Foot Pedal-Style Brakes (OSK-1071)

PITTSBURGH, Aug. 6, 2025 /PRNewswire/ -- "I wanted to create a way to lock a foot-operated parking brake pedal to protect against potential car...

GUNNAR Optiks and 2K Games Drop Borderlands 4-Inspired ‘Ripper” Gaming and Sun Glasses

OCEANSIDE, Calif., Aug. 6, 2025 /PRNewswire/ -- GUNNAR Optiks, the leading force in digital eye strain reduction and blue light blocking eyewear pioneer for...

CENTURY LITHIUM’S ANGEL ISLAND ADDED TO FAST-41 TRANSPARENCY STATUS

VANCOUVER, BC, Aug. 6, 2025 /PRNewswire/ - Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) ("Century Lithium" or "the Company") is pleased to...

CENTURY LITHIUM’S ANGEL ISLAND ADDED TO FAST-41 TRANSPARENCY STATUS

VANCOUVER, BC, Aug. 6, 2025 /CNW/ - Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) ("Century Lithium" or "the Company") is pleased to...

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders.

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatent